<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335800">
  <stage>Registered</stage>
  <submitdate>5/08/2010</submitdate>
  <approvaldate>6/08/2010</approvaldate>
  <actrnumber>ACTRN12610000640000</actrnumber>
  <trial_identification>
    <studytitle>Assessment of potential effects of elinogrel on steady-state pharmacokinetics of atorvastatin in healthy adult subjects</studytitle>
    <scientifictitle>An open-label, randomized, 2-way, cross-over study, to assess the potential effect of elinogrel on the steady-state pharmacokinetics of atorvastatin in healthy adult subjects</scientifictitle>
    <utrn>U1111-1116-3890</utrn>
    <trialacronym />
    <secondaryid>No secondary ID</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>acute coronary syndromes</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Atorvastatin 40 mg (oral tablet) once daily (QD) plus Elinogrel 150mg (oral capsule) twice daily (BD) for 5 days (treatment 2)

Each participant will take both treatments 1 and 2. One at a time, seperated by a 5 day washout period. The treatment  taken first will depend on randomistion (similar to the flip of a coin)</interventions>
    <comparator>Atorvastatin 40 mg (oral tablet) once daily (QD) alone for 5 days (treatment 1).  Patients in this arm will not take Elinogrel.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetic samples. 
Steady state pharmacokinetics of multiple doses of atorvastatin when adminstered with and without elinogrel in healthy adults</outcome>
      <timepoint>24 hours after the morning dose given on day 5 of each treatment period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments (electrocardiogram (ECG), vitals signs including pulse rate, blood pressure, body temperature, safety bloods, hematology, biochemistry and urinalysis, bleeding time tests, fecal occult blood, adverse events and serious adverse events)</outcome>
      <timepoint>From the time of first dose until the end of study visit.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- adult subjects aged 18 to 45
- Body Mass Index (BMI) between 18 and 32 Kg/m2
- Change between seated and standing blood pressure less than 20 mmHg for systolic blood pressure and 10 mmHg for diastolic blood pressure.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- Women of childbearing potential unless using suitable contraception methods
- Bleeding time tests out of normal laboratory range
- Abnormal liver function test results
- Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>20/08/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Nucleus Network</primarysponsorname>
    <primarysponsoraddress>Level 5 Burnet Institute 
Alfred Medical Research Education Precinct (AMREP)
89 Commercial Road, Melbourne 
Victoria 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceutical Pty Ltd</fundingname>
      <fundingaddress>54 Waterloo Rd
North Ryde NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Alfred Health</sponsorname>
      <sponsoraddress>89 Commercial Road, Melbourne
Victoria 3004</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Elinogrel is under development for the treatment of patients with chronic coronary heart disease and acute coronary syndromes. 
Patients treated for these conditions are likley to be on a statin therapy such as atorvastatin in addition to other anticoagulants such as elinogrel. 
Hence the need to investigate the potential drug-drug interaction between elinogrel and atorvastatin.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Health</ethicname>
      <ethicaddress>89 Commercial Road
Melbourne 
Victoria 3004</ethicaddress>
      <ethicapprovaldate>2/08/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>30/06/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christian Skulina</name>
      <address>54 Waterloo Rd 
North Ryde NSW 2113</address>
      <phone>+61 2 9805 3518</phone>
      <fax />
      <email>christian.skulina@novartis.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Karissa Fitzgerald</name>
      <address>54 Waterloo Rd 
North Ryde NSW 2113</address>
      <phone>+61 2 9805 3447</phone>
      <fax />
      <email>karissa.fitzgerald@novartis.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>